OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (249)	7/14/2005 2:19:05 PM
From: tom pope	Read Replies (1) of 447

Same thing? TORONTO (CP) - A new drug has been found, for the first time, to prolong the lives of patients with advanced lung cancer, a Canadian-led international research team says. Patients with end-stage lung cancer who were given Tarceva lived longer than patients given a placebo, said the study co-ordinated by the National Cancer Institute of Canada. About a third of the patients with non-small cell lung cancer - the most common type of the cancer - were alive for a year or more on the drug compared to about one-fifth of those on the dummy pill, said principal investigator Dr. Frances Shepherd. "This is very significant because this is the first time that any treatment has been shown to prolong survival for patients with lung cancer after they've failed chemotherapy," Shepherd said. "So this is a major step forward." Tarceva, known generically as erlotinib and co-marketed by OSI Pharmaceuticals and Genentech, is one of a new class of drugs that slows down tumour growth by interfering with a specific cellular pathway that promotes cell division. It is taken in pill form once a day.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next